Olink Holding AB

Olink Holding AB provides accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. The firm offers a platform of products and services which are deployed across major biopharmaceutical companies and clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. It operates through the following segments: Kit and Service. The company was founded on December 13, 2018 and is headquartered in Uppsala, Sweden.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Olink Holding AB exceeds revenue goals, eyes proteomics market growth

Olink had a successful Q4 and 2022, exceeding revenue goals and showcasing innovation.
The company is poised for growth in the proteomics market with a focus on data quality.
Challenges include shifting revenue mix, expanding installations, and meeting customer demands.
Opportunities lie in developing new assays, expanding the protein library, and leveraging positive customer feedback.

Olink Holding AB reports robust Q1 growth and eyes profitability

Olink Holding AB's Q1 2023 performance reflects strong revenue growth and a focus on innovation in next-generation proteomics.
Despite challenges in certain regions and operating at a net loss, the company maintains positive cash flow and aims for profitability in 2023.
Opportunities lie in market expansion, M&A activities, and improving kit gross margins through R&D efforts.
Overall, Olink's unique positioning in the life science space and commitment to serving diverse customer needs underpin its growth potential.

Olink Holding AB (OLK) sees strong revenue growth and market optimism

Olink Holding AB (OLK) reports solid revenue growth in Q2 2023, driven by Explore revenue and scientific productivity. Despite challenges in profitability and margin improvements, the company is optimistic about the market impact of Explore HT and back-half growth potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Olink Holding AB is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science.

Olink Holding AB (publ) Sponsored ADR (OLK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Olink Holding AB (publ) Sponsored ADR (OLK): Can Its 66.0% Jump Turn into More Strength?

Thermo Fisher Scientific

Olink Holding AB shares surged 66% to $24.87 in late-morning trading on Tuesday after the provider of next-generation proteomics solutions announced that it has agreed to be acquired by Thermo Fisher Scientific (NYSE:TMO) Inc for $26 per share in cash, representing a premium of about 74% to the closing price of Olink's Nasdaq-listed American Depositary Shares (ADS) on October 16, 2023.  The transaction values Olink at approximately $3.1 billion, which includes net cash of about $143 million.

Olink Holding stock soars on acquisition by Thermo Fisher Scientific

Thermo Fisher Scientific plans to acquire Olink for $3.1 billion. The deal would add Olink's proteomics technology to Thermo Fisher's life sciences solutions.

Why Olink Stock Is Skyrocketing Today

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Olink Holding AB (publ) (NASDAQ: OLK) to Thermo Fisher Scientific Inc. for $26.00 per common share in cash is fair to Olink shareholders. Halper Sadeh encourages Olink shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns wh.

OLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Olink Holding AB (publ) Is Fair to Shareholders

Thermo Fisher will acquire proteomics company Olink for $26 per American depositary share in cash.

Thermo Fisher to Buy Sweden's Olink for $3.1 Billion

Thermo Fisher Scientific Inc. TMO, +1.18% announced Tuesday an agreement to buy Sweden-based proteomics company Olink Holding AB OLK, +0.47% in a deal that values Olink at about $3.1 billion, including $143 million in cash. Olink's stock was halted for news until 8:50 a.m.

Thermo Fisher's stock slips after deal to buy Sweden's Olink for a 74% premium

WALTHAM, Mass. & UPPSALA, Sweden--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, and Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions, today announced that their respective boards of directors have approved Thermo Fisher's proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share (ADS) in cash. This represents a pre.

Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics

UPPSALA, Sweden, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today reported the publication of three articles in the prestigious scientific journal, Nature, that demonstrate the power of the Olink Explore platform for driving impactful proteogenomic studies at the population scale. The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 biopharmaceutical companies generated new proteomic data from accessing the UK Biobank.

Landmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics

Discover more with less. Unmatched specificity and sensitivity deliver translational insights from 1µl of sample. Discover more with less. Unmatched specificity and sensitivity deliver translational insights from 1µl of sample.

Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research.

Uppsala, Sweden, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Eurofins Genomics a dopts Olink ® technology to advance proteomics research and accelerate precision medicine programs

Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs

UPPSALA, Sweden, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events:

Olink to participate in September investor events

Olink Holding AB (publ) (NASDAQ:OLK ) Q2 2023 Earnings Conference Call August 9, 2023 8:00 AM ET Company Participants Jan Medina - VP, IR & Capital Markets Jon Heimer - CEO & Director Carl Raimond - President Oskar Hjelm - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Puneet Souda - Leerink Partners Sung Ji Nam - Scotiabank Matthew Sykes - Goldman Sachs Group Yuko Oku - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Olink Proteomics Q2 2023 Earnings Conference Call.

Olink Holding AB (publ) (OLK) Q2 2023 Earnings Call Transcript

Olink Holding AB (publ) Sponsored ADR (OLK) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.04 per share a year ago.

Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q2 Loss, Misses Revenue Estimates

UPPSALA, Sweden, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) has selected the Olink Explore platform as a proteomics component of their world-class multiomics offering.

Baylor College of Medicine Human Genome Sequencing Center adopts Olink® Explore HT proteomics platform

The average of price targets set by Wall Street analysts indicates a potential upside of 31.2% in Olink Holding AB (publ) Sponsored ADR (OLK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Olink Holding AB (publ) Sponsored ADR (OLK) Could Rally 31.22%: Here's is How to Trade

UPPSALA, Sweden, July 13, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the second quarter of 2023 before the market open on Wednesday, August 9, 2023. Company management will host a conference call to discuss these results at 8:00 am ET.

Olink to report second quarter 2023 financial results on August 9, 2023, and to participate in the Canaccord Genuity 43rd Annual Growth Conference

A High-throughput Protein Biomarker Discovery Platform with Proven Specificity at Any Scale A High-throughput Protein Biomarker Discovery Platform with Proven Specificity at Any Scale

Announcing Olink® Explore HT – A New Era in Proteomics

UPPSALA, Sweden, June 28, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the availability of new findings into the variability of the human proteome, based on measurements of approximately 1,500 proteins in over 50,000 participants from the UK Biobank (UKB). The findings will be shared through the Normal Ranges tool on Olink Insight, providing researchers with an unprecedented view into the biological variations in protein levels, measured for the first time at population scale. This unique dataset represents a dramatic expansion of the information presented in Olink Insight and promises to significantly advance scientific understanding of the human proteome.

Revealing the secrets of the human proteome with Olink® Insight: Exploring findings from one of the world's largest health studies

UPPSALA, Sweden, May 25, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events:

Olink to participate in June investor events

Olink Holding AB (publ) (NASDAQ:OLK ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Jan Medina - Vice President of Investor Relations and Capital Markets Jon Heimer - Chief Executive Officer Carl Raimond - President Oskar Hjelm - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Leerink Sung Ji Nam - Scotiabank Kyle Mikson - Canaccord Genuity Ivy Kozlowski - Goldman Sachs Operator Good morning, and thank you for standing by. Welcome to the Olink Proteomics Fourth Quarter 2022 Earnings Conference Call.

Olink Holding AB (publ) (OLK) Q1 2023 Earnings Call Transcript

Olink Holding AB (publ) Sponsored ADR (OLK) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.10 per share a year ago.

Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q1 Loss, Tops Revenue Estimates

UPPSALA, Sweden, May 11, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the first quarter ended March 31, 2023.

Olink reports first quarter 2023 financial results

Olink Holding AB (publ) Sponsored ADR (OLK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Olink Holding AB (publ) Sponsored ADR (OLK) Moves to Strong Buy: Rationale Behind the Upgrade

UPPSALA, Sweden, April 17, 2023 (GLOBE NEWSWIRE) -- At the A nnual G eneral M eeting (the “AGM”) of Olink Holding AB (publ), reg. no 55 9189 - 7755 , (the “Company”), on 1 7 April 202 3 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company's website, www. olink .com .

Report from the Annual General Meeting of Olink Holding AB (publ) on 17 April 2023

UPPSALA, Sweden, April 13, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the first quarter of 2023 before the market open on Thursday, May 11, 2023. Company management will host a conference call to discuss these results at 8:00 am ET.

News for Olink Holding AB Stock (OLK)